(HealthDay News) — Nasal glucagon can effectively and efficiently manage moderate or severe hypoglycemic episodes (HEs) in real-world settings in adult patients with type 1 diabetes, according to a ...
Each Baqsimi device includes 1 dose of glucagon and cannot be refused. The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of ...
Glucagon prescriptions for severe hypoglycemia in Medicaid initially decreased from 2012 to 2018 but increased between 2019 and 2023 following the introduction of newer products. Glucagon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results